Translational oncology closes the gap between laboratory research and clinical use, with the goal of translating scientific discoveries into successful cancer therapies. The session "Translational Oncology" is dedicated to strategies, innovation, and case studies that speed the process from bench to bedside.".
It's an approach through which molecular targets are identified, validated therapeutic candidates are selected, and clinical trials are designed that translate preclinical observations into the treatment of patients. Translational oncology focusses on multidisciplinary cooperation between molecular biology, pharmacology, genomics, and clinical science to create new therapies. Translational oncology also tackles problems in therapy resistance, biomarker identification, and individualized treatment regimens.
The session discusses progress in preclinical models, such as organoids, patient-derived xenografts, and in silico simulation, which drive understanding of tumor biology and are used to predict response to treatment. Integration of genomic analysis and bioinformatics allows precision medicine strategies, so that discoveries reach the correct patients.
Participants will learn about the translation of research into practice, new innovations, and trending developments in oncology. This presentation highlights translational research as a key to optimizing patient outcomes, streamlining therapeutic development, and defining cancer care for the future.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
